243 related articles for article (PubMed ID: 19695316)
21. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.
Ward KW; Smith BR
Drug Metab Dispos; 2004 Jun; 32(6):603-11. PubMed ID: 15155551
[TBL] [Abstract][Full Text] [Related]
22. Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
Rebiere H; Maggio AF; Gimeno P; Levaillant D; Civade C; Bonnet PA; Tissier MH
Pharmeur Sci Notes; 2008 Feb; 2008(1):17-20. PubMed ID: 18430402
[TBL] [Abstract][Full Text] [Related]
23. Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys.
Prueksaritanont T; Li C; Tang C; Kuo Y; Strong-Basalyga K; Carr B
Drug Metab Dispos; 2006 Nov; 34(11):1806-10. PubMed ID: 16928785
[TBL] [Abstract][Full Text] [Related]
24. Physiologically based toxicokinetic modelling as a tool to assess target organ toxicity in route-to-route extrapolation--the case of coumarin.
Mielke H; Abraham K; Götz M; Vieth B; Lampen A; Luch A; Gundert-Remy U
Toxicol Lett; 2011 Apr; 202(2):100-10. PubMed ID: 21291965
[TBL] [Abstract][Full Text] [Related]
25. Interspecies prediction of human drug clearance based on scaling data from one or two animal species.
Tang H; Hussain A; Leal M; Mayersohn M; Fluhler E
Drug Metab Dispos; 2007 Oct; 35(10):1886-93. PubMed ID: 17646280
[TBL] [Abstract][Full Text] [Related]
26. Interspecies allometric scaling. Part I: prediction of clearance in large animals.
Mahmood I; Martinez M; Hunter RP
J Vet Pharmacol Ther; 2006 Oct; 29(5):415-23. PubMed ID: 16958787
[TBL] [Abstract][Full Text] [Related]
27. The use of C(av) rather than AUC in safety assessment.
Smith DA; Morgan P; Vogel WM; Walker DK
Regul Toxicol Pharmacol; 2010 Jun; 57(1):70-3. PubMed ID: 20074607
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time.
Ward KW; Smith BR
Drug Metab Dispos; 2004 Jun; 32(6):612-9. PubMed ID: 15155552
[TBL] [Abstract][Full Text] [Related]
29. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
[TBL] [Abstract][Full Text] [Related]
30. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens.
Doak SH; Jenkins GJ; Johnson GE; Quick E; Parry EM; Parry JM
Cancer Res; 2007 Apr; 67(8):3904-11. PubMed ID: 17440105
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans.
Olsen GW; Chang SC; Noker PE; Gorman GS; Ehresman DJ; Lieder PH; Butenhoff JL
Toxicology; 2009 Feb; 256(1-2):65-74. PubMed ID: 19059455
[TBL] [Abstract][Full Text] [Related]
33. Ameliorative effects of vitamin supplementation on ethyl methane sulphonate-induced genotoxicity in a fish, Anabas testudineus.
Guha B; Das JK; Khuda-Bukhsh AR
Ecotoxicol Environ Saf; 2007 Sep; 68(1):63-70. PubMed ID: 16904744
[TBL] [Abstract][Full Text] [Related]
34. Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone.
Bonifácio MJ; Loureiro AI; Torrão L; Fernandes-Lopes C; Wright L; Pinho MJ; Soares-da-Silva P
Biochem Pharmacol; 2009 Oct; 78(8):1043-51. PubMed ID: 19505437
[TBL] [Abstract][Full Text] [Related]
35. Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):803-28. PubMed ID: 17637173
[TBL] [Abstract][Full Text] [Related]
36. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
37. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
[TBL] [Abstract][Full Text] [Related]
38. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
Kiriyama A; Honbo A; Iga K
Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
[TBL] [Abstract][Full Text] [Related]
39. Health assessment of phosgene: approaches for derivation of reference concentration.
Gift JS; McGaughy R; Singh DV; Sonawane B
Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
[TBL] [Abstract][Full Text] [Related]
40. Utility of the coefficient of determination (r2) in assessing the accuracy of interspecies allometric predictions: illumination or illusion?
Tang H; Mayersohn M
Drug Metab Dispos; 2007 Dec; 35(12):2139-42. PubMed ID: 17761780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
